Atlas Capital Advisors LLC Purchases 600 Shares of Pfizer Inc. (NYSE:PFE)

Atlas Capital Advisors LLC increased its position in Pfizer Inc. (NYSE:PFE) by 54.4% in the first quarter, Holdings Channel.com reports. The firm owned 1,702 shares of the biopharmaceutical company’s stock after acquiring an additional 600 shares during the period. Atlas Capital Advisors LLC’s holdings in Pfizer were worth $47,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Advisor OS LLC boosted its stake in Pfizer by 1.0% in the fourth quarter. Advisor OS LLC now owns 35,202 shares of the biopharmaceutical company’s stock valued at $1,013,000 after acquiring an additional 365 shares during the last quarter. Safeguard Investment Advisory Group LLC boosted its position in shares of Pfizer by 3.9% in the 4th quarter. Safeguard Investment Advisory Group LLC now owns 9,987 shares of the biopharmaceutical company’s stock worth $288,000 after purchasing an additional 371 shares during the last quarter. Lantz Financial LLC grew its stake in shares of Pfizer by 1.3% during the first quarter. Lantz Financial LLC now owns 30,582 shares of the biopharmaceutical company’s stock worth $849,000 after purchasing an additional 381 shares during the period. King Wealth Management Group increased its holdings in Pfizer by 2.4% in the fourth quarter. King Wealth Management Group now owns 16,686 shares of the biopharmaceutical company’s stock valued at $480,000 after purchasing an additional 388 shares during the last quarter. Finally, Advance Capital Management Inc. lifted its stake in Pfizer by 4.0% in the fourth quarter. Advance Capital Management Inc. now owns 10,177 shares of the biopharmaceutical company’s stock valued at $293,000 after buying an additional 391 shares during the period. 68.36% of the stock is owned by institutional investors.

Pfizer Price Performance

Shares of PFE stock opened at $27.80 on Friday. The firm’s fifty day moving average price is $27.81 and its two-hundred day moving average price is $27.69. The company has a current ratio of 1.05, a quick ratio of 0.78 and a debt-to-equity ratio of 0.66. Pfizer Inc. has a 1 year low of $25.20 and a 1 year high of $37.80.

Pfizer (NYSE:PFE) last released its earnings results on Wednesday, May 1st. The biopharmaceutical company reported $0.82 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.56 by $0.26. Pfizer had a positive return on equity of 8.64% and a negative net margin of 0.56%. The business had revenue of $14.88 billion for the quarter, compared to the consensus estimate of $13.87 billion. During the same quarter in the previous year, the business earned $1.23 earnings per share. Pfizer’s quarterly revenue was down 19.5% on a year-over-year basis. As a group, analysts expect that Pfizer Inc. will post 2.38 EPS for the current year.

Pfizer Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 3rd. Stockholders of record on Friday, July 26th will be issued a $0.42 dividend. This represents a $1.68 annualized dividend and a dividend yield of 6.04%. The ex-dividend date of this dividend is Friday, July 26th. Pfizer’s payout ratio is presently -2,799.53%.

Analysts Set New Price Targets

PFE has been the subject of a number of recent analyst reports. BMO Capital Markets reaffirmed an “outperform” rating and issued a $36.00 price target (up from $33.00) on shares of Pfizer in a research note on Thursday, May 2nd. Morgan Stanley raised their price objective on Pfizer from $28.00 to $29.00 and gave the stock an “equal weight” rating in a research note on Thursday, May 2nd. Argus cut Pfizer from a “buy” rating to a “hold” rating in a research note on Friday, March 22nd. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $45.00 price target on shares of Pfizer in a research report on Wednesday. Ten research analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. According to data from MarketBeat, Pfizer presently has a consensus rating of “Hold” and an average price target of $35.86.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.